BMRNBioMarin Pharmaceutical Inc.

$12B

Q3 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$392M+17.2% YoY

Gross Profit

$313M79.9% margin

Operating Income

-$16M-4.0% margin

Net Income

-$13M-3.2% margin

EPS (Diluted)

$-0.07

QoQ Revenue Growth

+5.1%

Cash Flow

Operating Cash Flow

$47M

Free Cash Flow

-$3M

Stock-Based Comp.

$37M

Balance Sheet

Total Assets

$4.7B

Total Liabilities

$1.8B

Stockholders' Equity

$2.9B

Cash & Equivalents

$882M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$392M	$334M	+17.2%
Gross Profit	$313M	$275M	+13.9%
Operating Income	-$16M	-$14M	-14.7%
Net Income	-$13M	-$13M	-0.7%

Revenue Segments

Product

$386M50%

Product Four

$123M16%

Product Three

$113M15%

Product Two

$103M13%

Product One

$28M4%

Product Six

$10M1%

Product Five

$5M1%

Product Seven

$4M1%

Geographic Segments

UNITED STATES

$175M45%

Europe

$111M28%

Latin America

$55M14%

Rest Of World

$51M13%

BMRN Q3 2018 Earnings — BioMarin Pharmaceutical Inc. Revenue & Financial Results | Market Cap Arena